<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421538</url>
  </required_header>
  <id_info>
    <org_study_id>3200B0-105991</org_study_id>
    <secondary_id>CACTUS-PTS Trial</secondary_id>
    <nct_id>NCT00421538</nct_id>
    <nct_alias>NCT00539058</nct_alias>
  </id_info>
  <brief_title>Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)</brief_title>
  <acronym>CACTUS-PTS</acronym>
  <official_title>Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lady Davis Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CACTUS-PTS is a randomized, placebo-controlled, double-blind study which aims primarily to&#xD;
      determine the effectiveness of a 6 week course of therapeutic-dose LMWH (nadroparine)&#xD;
      injections vs. placebo in patients with a first symptomatic isolated distal (calf) deep-vein&#xD;
      thrombosis (IDDVT), as measured by rate of proximal DVT and symptomatic PE at 6 weeks.&#xD;
      Additionally, the study aims to determine if the 6 week course of treatment with&#xD;
      therapeutic-dose LMWH (nadroparine) injections, compared to placebo, decreases the frequency&#xD;
      of post-thrombotic syndrome (PTS) at 1 year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CACTUS-PTS study will compare anticoagulant treatment for 6 weeks versus placebo in&#xD;
      acute, symptomatic distal DVT. Patients will be randomized to receive either a six-week&#xD;
      period of LMWH at therapeutic dosage or a six-week period of placebo. All patients will be&#xD;
      treated with elastic compression stockings and followed-up with a standardized&#xD;
      ultrasonography protocol. Strict ultrasonographic diagnostic criteria for distal DVT have&#xD;
      been defined. Control compression ultrasonography will be performed between days 3 and 7 and&#xD;
      at six weeks after inclusion. The primary outcome will be a composite of the proportion of&#xD;
      patients with extension of the thrombus to the proximal veins (detected by the programmed&#xD;
      ultrasound examinations or by an ultrasound performed because of recurrent symptoms) or&#xD;
      symptomatic PE in both arms of the study during the 6-weeks study period. Patients with such&#xD;
      an outcome will be anticoagulated as currently admitted in presence of a proximal DVT.&#xD;
      Secondary outcomes will be the individual components of the composite endpoint (distal DVT&#xD;
      extension to proximal veins; symptomatic PE), major bleeding, serious adverse events and&#xD;
      death reported at 6 weeks and 90 days. To answer the research question of the PTS add-on&#xD;
      study, patients will self-assess and be assessed for PTS by a clinician using the Villalta&#xD;
      scale, 1 year following their enrolment into the trial. In addition, patients will complete a&#xD;
      Quality of Life (QOL) questionnaire. The QOL questionnaire will be comprised of both the&#xD;
      VEINES-QOL and SF-36. The primary outcome is the rate of PTS, with secondary outcomes of QOL&#xD;
      scores and PTS severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of rate of extension of distal DVT to proximal deep veins (includes ipsilateral extension or new contralateral proximal DVT) or symptomatic PE at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of post-thrombotic syndrome (PTS)</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of post-thrombotic syndrome (PTS) diagnosed using the Villalta scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual components of the composite endpoint: distal DVT extension to proximal veins at 6 weeks and 90 days; PE at 6 weeks and 90 days</measure>
    <time_frame>6 weeks and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding at 6 weeks and 90 days</measure>
    <time_frame>6 weeks and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death at 6 weeks and 90 days</measure>
    <time_frame>6 weeks and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events at 6 weeks and 90 days</measure>
    <time_frame>6 weeks and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic and venous disease-specific Quality of Life scores</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTS severity category</measure>
    <time_frame>1 year</time_frame>
    <description>Can either be mild, intermediate, severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Distal (Calf) Deep-vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>LMWH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapeutic dose of Nadroparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injectable placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nadroparine calcium</intervention_name>
    <description>Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.</description>
    <arm_group_label>LMWH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All outpatients with an acute, symptomatic, distal DVT will be included in the study,&#xD;
             provided they correspond to the following diagnostic and exclusion criteria, and they&#xD;
             have signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Previously objectively diagnosed DVT or PE&#xD;
&#xD;
          -  Distal DVT involving the tibioperoneal trunk (i.e. calf trifurcation)&#xD;
&#xD;
          -  Clinically suspected pulmonary embolism&#xD;
&#xD;
          -  Active cancer, receiving cancer treatment or cancer considered cured for &lt;6 months&#xD;
&#xD;
          -  Ipsilateral or contralateral proximal DVT&#xD;
&#xD;
          -  Indication for long-term anticoagulation (e.g. atrial fibrillation, mechanical heart&#xD;
             valve...)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt; 100 g/l)&#xD;
&#xD;
          -  Impaired renal function (serum creatinine &gt; 180 micromol/l or clearance to creatinine&#xD;
             less than 30 ml/min)&#xD;
&#xD;
          -  Known hypersensitivity to heparin&#xD;
&#xD;
          -  Presence of an active bleeding or a pathology susceptible of bleeding in presence of&#xD;
             anticoagulation (gastric ulcer, cerebral malignant disease...)&#xD;
&#xD;
          -  Treatment with daily NSAIDs (aspirin ≤160 mg/day permitted)&#xD;
&#xD;
          -  Body weight &gt;115 kg or &lt;40 kg&#xD;
&#xD;
          -  Treatment with therapeutic doses of anticoagulants for &gt;2 days, corresponding to: 2&#xD;
             injections of LMWH if once daily therapeutic LMWH used; 3 injections of LMWH if&#xD;
             twice-daily therapeutic LMWH used; 1 dose of oral vitamin K antagonist (e.g. warfarin)&#xD;
&#xD;
          -  Ongoing requirement for prophylactic dose thromboprophylaxis (e.g. acute post-op&#xD;
             patient receiving thromboprophylaxis)&#xD;
&#xD;
          -  Enrolled in another clinical trial within previous 30 days&#xD;
&#xD;
          -  Inability or refusal to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Righini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Quéré, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Kahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Carrier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Marc Righini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Deep vein Thrombosis</keyword>
  <keyword>Calf vein thrombosis</keyword>
  <keyword>Low-molecular weight heparin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Elastic contention</keyword>
  <keyword>Compression Ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadroparin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

